Tag

Your search for Global HCV returned 12 results.


Exclusive HCV Interview: Julio Gutierrez, MD

So my first question is what do you see as the biggest challenges associated with the hepatitis C epidemic in the U.S.? JULIO GUTIERREZ: There are three main challenges currently associated with eradicating hepatitis C in the United States: Most patients in the US are still not receiving care for their hepatitis C infection. In order to cure HCV in these ...

Read More


Two DAA regimen in cirrhotic HCV GT1b patients

New Phase 2 clinical trial results indicate that an all-oral interferon- and ribavirin-free regimen of ombitasvir, paritaprevir, and ritonavir is generally well tolerated and associated with high rates of SVR12 in both cirrhotic and noncirrhotic patients with HCV genotype 1b infection who were treatment-naive or treatment experienced, including prior null responders, ...

Read More


GS-5816: a DAA with pan-genotypic HCV activity

The availability of a safe, highly effective, pangenotypic regimen for the treatment of HCV infection would have a major impact on global disease prevalence, as it would be suitable for treatment of all infected persons regardless of genotype. Results of a new phase 1 study demonstrate the safety and potent pan-genotypic HCV activity of GS-5816, a novel inhibitor of ...

Read More


Largest DAA study to date in HCV genotype 4

Largest study to date shows that the two direct-acting antiviral drug-only regimen (ombitasvir plus paritaprevir) is effective and well tolerated in both treatment-naive and treatment-experienced patients with HCV genotype 4 infection without cirrhosis. Note that patients also received low-dose ritonavir to increase paritaprevir peak and trough concentrations and ...

Read More


Special Interview on HCV: Dr. S. Wiktor of WHO

Thank you for agreeing to participate in this special interview on HCV. What do you see as the biggest global challenges in the diagnosis, screening, and treatment of hepatitis C? Dr. Wiktor: The landscape is changing very quickly and it is being driven by remarkable progress in the development of direct-acting antiviral therapies for hepatitis C. We hear ...

Read More


Real-world evaluation of eligibility for HCV therapy

In clinical practices in Italy, between January 2009 and February 2010, only 61% of patients with chronic hepatitis C were considered eligible for peginterferon/ribavirin. Reasons treatment was not indicated included patient’s age or mild disease stage. Italian Hepatologists may consider an IFN-based antiviral treatment not cost-effective in older patients ...

Read More


HCV therapy access reduces HCV-related deaths

A global reduction of HCV liver-related mortality is dependent on access to therapy Between 64 and 103 million individuals worldwide are estimated to be chronically infected with hepatitis C (HCV). Fortunately, with the advent of interferon-free therapy with SVR rates in pivotal phase 2 and 3 trials of between 92% and 100%, it’s possible to cure chronic HCV ...

Read More


Viral load quantification: Hepatitis therapy barrier

Hepatitis viral load quantification is lacking in low- and middle-income countries, and this is a major barrier to the provision of therapies to patients who need them Viral load quantification is considered a mandatory component of the diagnostic work-up in all international liver society guidelines. Low- and middle-income countries typically lack access to viral ...

Read More


Perfectovir is a realizable goal: an HCV revolution

The development of “Perfectovir” is a realizable goal: a revolution in the treatment of Hepatitis C has begun! The key attributes of an optimal HCV treatment regimen were recently outlined by Gregory Dore and Jordan Feld in an invited review article published in the journal Clinical Infectious Diseases (Dore GJ, Feld JJ. Clin Infect Dis. 2015 Mar 11. pii: ...

Read More


Hepatitis C is a Global Public Health Issue

Undiagnosed and Untreated Hepatitis C is a Global Public Health Issue Undiagnosed and untreated hepatitis C is a global public health issue, with growing numbers of patients suffering and dying from the consequences of chronic infection, including cirrhosis and hepatocellular carcinoma. HCV infection is typically asymptomatic until significant liver disease ...

Read More